 |
|
|
|
Home Destination Vector pCMV6-AC-FP602

PrecisionShuttle mammalian vector with C-terminal FP602 tag
| Catalog No. |
Description |
Price |
Availability |
| PS100037 |
PrecisionShuttle mammalian vector with C-terminal FP602 tag |
$560 |
In Stock |

Features:
- ORFs cloned in this vector will be expressed in mammalian cells as a tagged protein with a C-terminal TurboFP602 tag.
- TurboFP602 possesses true-red fluorescence (with excitation/emission maxima at 574/602 nm, respectively), optimal for detection via most popular filter sets, and is easily distinguished from background signals. TurboFP602 exhibits fast maturation and high pH stability.
TurboFP602 is mainly intended for applications where fast appearance of true-red fluorescence is crucial. It is specially recommended for cell and organelle labeling and for tracking the promoter activity in autofluorescent tissues. - If the C-terminal tagging interferes with the protein’s function, you can choose the N-terminal FP602-tagging vector, PS100045.
Schematic of the multiple cloning sites:
OriGene's fluorescent protein genes are all licensed from Evrogen. Plasmid vectors harboring a fluorescent protein gene contains a proprietary nucleic acid coding for a proprietary fluorescent proteins(s) intended to be used for not-for-profit internal research purposes only, where "research purposes" means non-conmmercial uses or activities which (or the results of which) do not generate revenue. Any use of the proprietary nucleic acid or protein other than for research use is strictly prohibited. USE IN ANY OTHER APPLICATION REQUIRES A LICENSE FROM EVROGEN. To obtain such a license, please contact Evrogen at license@evrogen.com.
All OriGene’s TrueORFs inserts can be subcloned into this vector via custom cloning service. To use this service:
- Find the gene of interest using any of the Gene Name, Gene Symbol, Accession Number or Keyword.
- At the product page displaying the correct gene of interest, choose the appropriate destination vector and select the “Custom Cloning” .
|

|